Advanced Viral Research Corp. Receives U.S. Patent Entitled ''Treatment of Basal Cell Carcinoma With Product R, a Peptide-Nucleic Acid Preparation''
Business Wire - May 13, 1999 09:32
YONKERS, N.Y.--(BW HealthWire)--May 13, 1999--Advanced Viral Research Corp. (OTC
BB:ADVR) announced the award of U.S. Patent No. 5,902,786 in May 1999 titled, "Treatment
of basal cell carcinoma with product R, a peptide-nucleic acid preparation."
"Basal cell carcinoma is a common skin cancer often appearing on the face. The award of
another patent reflects the breadth of potential applications of our peptide-nucleic acid type
drugs," commented Dr. Shalom Z. Hirschman, president and CEO of Advanced Viral
Research Corp.
NOTE: This news release contains forward-looking statements that involve risks and
uncertainties, including risks associated with clinical development, regulatory approvals,
including application to the FDA, product commercialization and other risks described from
time to time in the SEC reports filed by ADVR. Reticulose is not approved by the U.S. Food
and Drug Administration or any comparable agencies of any other countries.
CONTACT: Advanced Viral Research Corp., Hallandale, Fla.
Mark Amster, 954/458-7636 |
